Meeting
2023 ASCO Genitourinary Cancers Symposium
A phase 2 study of ibrutinib as neoadjuvant therapy in patients with localized prostate cancer.
Authors
Cayce Ben Nawaf
Washington University School of Medicine, St. Louis, MO
Cayce Ben Nawaf , Bo Peng , Melissa Andrea Reimers , Cody Weimholt , Kathryn Slane , Peter John Oppelt , Jason Frankel , Robert S. Figenshau , Eric H Kim , Gerald L. Andriole , Lawrence Fong , Russell Kent Pachynski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Clinical Trial Registration Number
NCT02643667
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 387)
DOI
10.1200/JCO.2023.41.6_suppl.387
Abstract #
387
Poster Bd #
P4
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: A multicenter, open-labeled, single-arm phase II trial.
First Author: Junlong Zhuang
Poster
2023 ASCO Genitourinary Cancers Symposium
A randomized phase II trial of neoadjuvant chemokine modulation in patients with localized prostate cancer undergoing radical prostatectomy.
First Author: Karan Jatwani
Poster
2020 Genitourinary Cancers Symposium
A phase Ib/II trial of perioperative intratumoral MVA-BN-brachyury (MVA) plus systemic PROSTVAC and atezolizumab (Atezo) for intermediate-risk and high-risk localized prostate cancer (AtezoVax).
First Author: Benjamin Louis Maughan
Poster
2018 ASCO Annual Meeting
Phase II neoadjuvant and immunologic study of B7-H3 targeting with enoblituzumab in localized intermediate- and high-risk prostate cancer.
First Author: Eugene Shenderov